There’s research and then theres research. I might be old fashioned - but to me when gnoring share price, especially ones in contract yes down trends would be poor research.
For example, a lot of people dug into research and posted that the Zenabis and Hexo combination would be a top 3 player in the world. Some predicted annual sales of $624 million (turned out to be about $180)
Zenabis declared bankruptcy and was acquired for pennies by SNDL who they owed $60 million to - and of course, Hexo would have been forced to bankruptcy if Tilray hadn't acquired them.
Those darn shorters